Company: ARTL
Filing Date: 2025-10-01
Form Type: 424B5
Source: 0001640334-25-001763
Chunk: 46

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-10-01
Form: 424B5
Chunk 46
---
 compared to non-cocrystal CBD compositions. We plan to develop ART12.11 for multiple potential indications where CBD has shown activity such anxiety disorders, including PTSD, depression, and Inflammatory Bowel Disease (“IBD”).   We are developing our product candidates in accordance with traditional regulated drug development standards and expect to make them available to patients via prescription or physician orders only after obtaining marketing authorization from a regulatory authority, such as the FDA. Our management team has experience developing, commercializing, and partnering ethical pharmaceutical products, including several first-in-class therapeutics. Based upon our current management’s capabilities and the future talent we may attract, we expect to retain rights to internally develop and commercialize products; however, we may seek collaborations with partners in the biopharmaceutical industry when that strategy serves to maximize value for our stockholders.   Product Candidate Pipeline: |

| Product Candidate                                  | Target Indications                                                                                         | Development Phase | Estimated Market Size                                                                                                               |
| ART27.13 – Synthetic Dual Cannabinoid GPCR Agonist | Anorexia associated with cancer                                                                            | Clinical          | Cancer anorexia cachexia syndrome: >$2 billion                                                                                      |
| ART26.12 – FABP5 inhibitor                         | Chemotherapy Induced Peripheral Neuropathy, Prostate cancer and Breast cancer, pain, and anxiety disorders | Pre-clinical      | CIPN: >$1 billion Prostate cancer: approximately $9 billion Breast cancer: approximately $18 billion PTSD: approximately $7 billion |
| ART12.11 – Synthetic CBD Cocrystal                 | Inflammatory Bowel Disease (IBD), Post-Traumatic Stress Disorder (PTSD), and other potential indications   | Pre-clinical      | IBD: approximately $7 billion PTSD: approximately $7 billion                                                                        |

| 5 |

| Background     The ECS is composed of cannabinoid receptors, endogenous receptor ligands (“endocannabinoids”) and their associated transporter mechanisms, as well as enzymes responsible for the synthesis and degradation of endocannabinoids and has emerged as a considerable target for pharmacotherapy approaches of numerous human diseases. As a widespread modulatory and lipid-signaling system, the ECS plays important roles in the CNS, development, synaptic plasticity, and the response to endogenous and environmental factors.   The modulation of the ECS can be affected by using selective or non-selective agonists, partial agonists, inverse agonists, and antagonists of the cannabinoid receptors, CB1 and CB2. The CB